Trimetazidine Hydrochloride

GREENWICH, Conn.--(BUSINESS WIRE)-- Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company poised to enter a Phase 3 study of ST-62516 (trimetazidine) to reduce the risk of cardiorenal complications after PCI, announced its participation at the Goldman Sachs 45th Annual Global Healthcare Conference. Anna Kazanchyan, MD, Saghmos’ Founder and Chief Executive Officer, is scheduled to present on Wednesday, June 12th at 3:20pm Eastern Time. A live webcast of the session will be accessible at . A replay of the webcast will be available shortly after the presentation. About Saghmos Therapeutics Saghmos is developing ST-62516 (trimetazidine), a cardiorenal metabolic modulator to reduce the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) after contrast procedures such as PCI. Over one million PCI procedures are performed annually in the US in patients with unstable angina (heart attack). About half of these patients have comorbidities which impact the safety of PCI. This is a major unmet medical need with no FDA-approved drugs available to prevent or treat AKI and MACKE. Forward looking statements This press release contains forward-looking statements, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Saghmos Therapeutics’ business, intellectual property, clinical and regulatory plans, commercial potential, and the value and benefits of ST-62516. In any forward-looking statement in which Saghmos expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Saghmos’ actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources, uncertainties and changes related to the law and regulatory process, and general changes in the economic environment. These forward-looking statements are based on our current expectations. Saghmos does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Patent has broad claims for the Reduction of Acute Kidney Injury in Patients with Chronic Kidney Disease Undergoing Procedures with Contrast Dyes Provides exclusivity through 2037 GREENWICH, Conn.--(BUSINESS WIRE)-- Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced that the Japanese Patent Office has issued Japanese Patent No. 7474463 for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator. The patent will provide exclusivity through 2037, with broad claims for the reduction of acute kidney injury in patients with chronic kidney disease (CKD) undergoing procedures with contrast dyes. "We are excited about the continued growth of Saghmos’ patent estate, with a new Japanese patent, in addition to the issued US patent and a Notice of Allowance for a second US patent,” commented Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. Saghmos is developing ST-62516 to reduce the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) after contrast procedures such as percutaneous coronary intervention (PCI). The company recently announced a collaboration with the Duke Clinical Research Institute (DCRI) to optimize all aspects of and plan the operationalization of Saghmos’ Phase 3 study. Over one million PCI procedures are performed annually in the US in people with ischemic heart disease, including myocardial infarction (heart attack). About half of these individuals have comorbidities such as chronic kidney disease, diabetes, or are aged 75 and older. These comorbidities, in combination with certain procedure-related factors, impact the safety of PCI and increase the risk of AKI and MACKE. This is a major unmet medical need with no FDA-approved drugs available. ST-62516 could benefit all people undergoing a PCI, not just those with comorbidities, by reducing the threat of AKI and MACKE after PCI. About Saghmos Therapeutics Saghmos Therapeutics is developing ST-62516 (trimetazidine) to reduce the risk of cardiorenal complications after PCI. The company has an issued US patent (Patent number 11,123,345) for the prevention and treatment of acute kidney injury after contrast procedures, and a Notice of Allowance for an additional patent in the US. Saghmos recently announced the appointment of Fred Hassan as Chairman of the Board of Directors and Dr. Stephen Grant as Chief Regulatory Officer. Forward looking statements This press release contains forward-looking statements, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Saghmos Therapeutics’ business, intellectual property, clinical and regulatory plans, commercial potential, and the value and benefits of ST-62516. In any forward-looking statement in which Saghmos expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Saghmos’ actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources, uncertainties and changes related to the law and regulatory process, and general changes in the economic environment. These forward-looking statements are based on our current expectations. Saghmos does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. View source version on businesswire.com: Contacts Saghmos Therapeutics, Inc. Anna Kazanchyan, MD Founder and CEO +1 914 522 3885 anna@saghmos.com or LaVoie Health Science Katie Dodge Senior Vice President +1 978 360 3151 kdodge@lavoiehealthscience.com Source: Saghmos Therapeutics, Inc. View this news release online at: